Marketdash
Back to News

Palvella's Skin Treatment Shows 73% Improvement Rate in Phase 2 Trial

MarketDash Editorial Team
7 hours ago
Palvella Therapeutics announced promising Phase 2 results for its QTORIN rapamycin gel treating cutaneous venous malformations, with 73% of participants showing improvement and most adverse events classified as mild to moderate.

Palvella Therapeutics, Inc. (PVLA) delivered some encouraging news Monday, sharing topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. If you're wondering what those are, think blue or purple spots on the skin or soft, squishy lumps that can cause pain, swelling, bleeding, or cosmetic concerns. They're benign vascular anomalies, but they can be genuinely bothersome for patients.

The trial measured results using the Overall Cutaneous Venous Malformations Investigator Global Assessment, which is essentially a seven-point scale where doctors rate how much things have changed from baseline. The scale runs from "Very Much Worse" (scored as -3) to "Very Much Improved" (+3), giving a pretty straightforward way to track whether the treatment is helping.

The Results at Week 12 Look Promising

Here's what the data showed: 73% of trial participants (that's 11 out of 15 people) improved overall. Even more impressive, 67% of participants (10 out of 15) hit the "Much Improved" or "Very Much Improved" marks on the assessment scale. Perhaps just as important, not a single participant got worse. Zero people scored in the "Minimally Worse," "Much Worse," or "Very Much Worse" categories.

On the safety front, QTORIN rapamycin was generally well tolerated. The most common treatment-related issue was application-site erythema (redness) affecting 25% of participants. All treatment-related adverse events were either mild or moderate, with nothing unexpected popping up. And here's something interesting: rapamycin levels stayed below the lower limit of quantification (2 ng/mL) in systemic circulation throughout the study, meaning the drug appears to stay where you put it rather than circulating through the body.

Beyond this trial, Palvella has been busy expanding its pipeline. Back in November, the company announced a new product candidate called QTORIN pitavastatin for treating disseminated superficial actinic porokeratosis, another rare skin condition. This new candidate was developed using QTORIN, the company's patented platform designed to create novel topical treatments for rare skin diseases.

Looking ahead, Palvella plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 trial for the pitavastatin candidate, with that trial expected to kick off in the second half of 2026.

Price Action: Palvella stock climbed 10.35% to $108.79 on Monday following the announcement.

Back to News

Palvella's Skin Treatment Shows 73% Improvement Rate in Phase 2 Trial

MarketDash Editorial Team
7 hours ago
Palvella Therapeutics announced promising Phase 2 results for its QTORIN rapamycin gel treating cutaneous venous malformations, with 73% of participants showing improvement and most adverse events classified as mild to moderate.

Palvella Therapeutics, Inc. (PVLA) delivered some encouraging news Monday, sharing topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for treating cutaneous venous malformations. If you're wondering what those are, think blue or purple spots on the skin or soft, squishy lumps that can cause pain, swelling, bleeding, or cosmetic concerns. They're benign vascular anomalies, but they can be genuinely bothersome for patients.

The trial measured results using the Overall Cutaneous Venous Malformations Investigator Global Assessment, which is essentially a seven-point scale where doctors rate how much things have changed from baseline. The scale runs from "Very Much Worse" (scored as -3) to "Very Much Improved" (+3), giving a pretty straightforward way to track whether the treatment is helping.

The Results at Week 12 Look Promising

Here's what the data showed: 73% of trial participants (that's 11 out of 15 people) improved overall. Even more impressive, 67% of participants (10 out of 15) hit the "Much Improved" or "Very Much Improved" marks on the assessment scale. Perhaps just as important, not a single participant got worse. Zero people scored in the "Minimally Worse," "Much Worse," or "Very Much Worse" categories.

On the safety front, QTORIN rapamycin was generally well tolerated. The most common treatment-related issue was application-site erythema (redness) affecting 25% of participants. All treatment-related adverse events were either mild or moderate, with nothing unexpected popping up. And here's something interesting: rapamycin levels stayed below the lower limit of quantification (2 ng/mL) in systemic circulation throughout the study, meaning the drug appears to stay where you put it rather than circulating through the body.

Beyond this trial, Palvella has been busy expanding its pipeline. Back in November, the company announced a new product candidate called QTORIN pitavastatin for treating disseminated superficial actinic porokeratosis, another rare skin condition. This new candidate was developed using QTORIN, the company's patented platform designed to create novel topical treatments for rare skin diseases.

Looking ahead, Palvella plans to meet with the FDA in the first half of 2026 to discuss the proposed design of a Phase 2 trial for the pitavastatin candidate, with that trial expected to kick off in the second half of 2026.

Price Action: Palvella stock climbed 10.35% to $108.79 on Monday following the announcement.